Enodia Therapeutics
Develops small-molecule therapies for targeted protein degradation at the point of synthesis
€20.7MSeed
Role not disclosedPV
Pfizer Ventures
Activity from announced rounds
Activity in this selectionFrance · Oct 12, 2026 · Jan 1, 2026
Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.
Recorded funding activity
TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $24.2M 1 disclosed · full round size, not this investor’s share